Market Overview:
The global Lennox-Gastaut Syndrome drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Lennox-Gastaut Syndrome, rising awareness about the condition, and increasing research and development activities for new drugs for treating Lennox-Gastaut Syndrome. The global Lennox-Gastaut Syndrome drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into perampanel, cannabidiol (CBD), NRP-2945 fenfluramine hydrochloride (Fenfluramine HCl), and others. On the basis of application, the market is segmented into hospital use, clinic use household use.
Product Definition:
Lennox-Gastaut Syndrome Drug is a type of anti-epileptic medication used to treat seizures in people with Lennox-Gastaut syndrome. It is not known exactly how the drug works to control seizures, but it is thought to help by preventing the spread of seizure activity in the brain.
Perampanel:
Perampanel is a new drug for LGS and has been granted fast track designation by the FDA. It is an anti-epileptic drug that prevents seizures by altering the electrical activity of brain cells through its receptor site. The drug was developed by Bayer AG, a German pharmaceutical company, as an add on therapy in patients who are already taking valproate (Depakote) or other antiseizure drugs.
Cannabidiol:
Cannabidiol (CBD) is a naturally occurring compound derived from the cannabis plant. It has become increasingly popular as an alternative treatment due to its non-narcotic properties. These properties have led to numerous research studies being conducted on cannabidiol, resulting in many new therapeutic applications and discoveries. Some of these include relaxation, pain relief, anti-epileptic effects, and others.
Application Insights:
Based on application, the global Lennox-Gastaut syndrome drug market is segmented into hospital, clinic and household. The hospital segment dominated the market in 2017 owing to increasing prevalence of LGS and growing awareness about treatment options for this condition. According to a study published in Neurology®, over 50% of patients with LGS die within five years due to complications associated with this disease. Thus, rising incidence rate of LGS coupled with high unmet medical needs drives demand for effective treatment options which is expected to fuel growth during the forecast period.
The household application segment is expected register fastest CAGR from 2018 to 2030 as many patients prefer self-medication due by lack of knowledge about available treatments or awareness regarding side effects related medication use at home which may result in under utilization of healthcare resources thus driving growth during the forecast period.
Regional Analysis:
North America held the largest share in the global lennox-gastaut syndrome drug market owing to favorable reimbursement policies, increasing R&D investments by companies and rising prevalence of the disease. In addition, growing awareness about SEGs is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period due to factors such as improving healthcare infrastructure and economic development in emerging countries like China & India. Moreover, an increase in epilepsy cases has been observed among children & adolescents which has led major players focus on developing novel therapies for Severe Epilepsy with Lennox-Gastaut Syndrome (SELPGS). This factor will also contribute towards regional expansion over next eight years.
Growth Factors:
- Increasing prevalence of Lennox-Gastaut Syndrome (LGS)
- Growing awareness about LGS among people and healthcare professionals
- Rising demand for better treatment options for LGS patients
- Availability of government funding for research on LGS drugs and therapies
- Technological advancements in the field of drug development
Scope Of The Report
Report Attributes
Report Details
Report Title
Lennox-Gastaut Syndrome Drug Market Research Report
By Type
Perampanel, Cannabidiol, NRP-2945, Fenfluramine Hydrochloride, Others
By Application
Hospital, Clinic, Household
By Companies
Eisai Co Ltd, GW Pharmaceuticals Plc, INSYS Therapeutics Inc, Zogenix Inc, Eisai Co Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Lennox-Gastaut Syndrome Drug Market Report Segments:
The global Lennox-Gastaut Syndrome Drug market is segmented on the basis of:
Types
Perampanel, Cannabidiol, NRP-2945, Fenfluramine Hydrochloride, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Household
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eisai Co Ltd
- GW Pharmaceuticals Plc
- INSYS Therapeutics Inc
- Zogenix Inc
- Eisai Co Ltd
Highlights of The Lennox-Gastaut Syndrome Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Perampanel
- Cannabidiol
- NRP-2945
- Fenfluramine Hydrochloride
- Others
- By Application:
- Hospital
- Clinic
- Household
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lennox-Gastaut Syndrome Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lennox-Gastaut Syndrome Drug is a medication used to treat seizures in people with Lennox-Gastaut Syndrome.
Some of the major players in the lennox-gastaut syndrome drug market are Eisai Co Ltd, GW Pharmaceuticals Plc, INSYS Therapeutics Inc, Zogenix Inc, Eisai Co Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lennox-Gastaut Syndrome Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lennox-Gastaut Syndrome Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lennox-Gastaut Syndrome Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lennox-Gastaut Syndrome Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lennox-Gastaut Syndrome Drug Market Size & Forecast, 2020-2028
4.5.1 Lennox-Gastaut Syndrome Drug Market Size and Y-o-Y Growth
4.5.2 Lennox-Gastaut Syndrome Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Perampanel
5.2.2 Cannabidiol
5.2.3 NRP-2945
5.2.4 Fenfluramine Hydrochloride
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Household
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lennox-Gastaut Syndrome Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lennox-Gastaut Syndrome Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Perampanel
9.6.2 Cannabidiol
9.6.3 NRP-2945
9.6.4 Fenfluramine Hydrochloride
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Household
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Perampanel
10.6.2 Cannabidiol
10.6.3 NRP-2945
10.6.4 Fenfluramine Hydrochloride
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Household
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Perampanel
11.6.2 Cannabidiol
11.6.3 NRP-2945
11.6.4 Fenfluramine Hydrochloride
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Household
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Perampanel
12.6.2 Cannabidiol
12.6.3 NRP-2945
12.6.4 Fenfluramine Hydrochloride
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Household
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Perampanel
13.6.2 Cannabidiol
13.6.3 NRP-2945
13.6.4 Fenfluramine Hydrochloride
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Household
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lennox-Gastaut Syndrome Drug Market: Competitive Dashboard
14.2 Global Lennox-Gastaut Syndrome Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eisai Co Ltd
14.3.2 GW Pharmaceuticals Plc
14.3.3 INSYS Therapeutics Inc
14.3.4 Zogenix Inc
14.3.5 Eisai Co Ltd
